Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

24.47USD
22 Sep 2017
Change (% chg)

$-3.54 (-12.64%)
Prev Close
$28.01
Open
$27.00
Day's High
$27.01
Day's Low
$24.07
Volume
10,839,457
Avg. Vol
4,064,860
52-wk High
$29.50
52-wk Low
$10.04

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $7,191.85
Shares Outstanding(Mil.): 293.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 81.40 16.08
EPS (TTM): -- -- --
ROI: -- 3.18 14.60
ROE: -- 4.93 14.03

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Sep 11 2017

BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer

* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:

Aug 16 2017

BRIEF-Exelixis announces settlement of dispute with Genentech

* Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib

Jul 20 2017

BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial

* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Jul 10 2017

BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Jun 19 2017

BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN

* Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Jun 19 2017

BRIEF-Exelixis announces initiation of early-stage trial of combination drug

* Exelixis Inc announces initiation of Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors Source text for Eikon: Further company coverage:

Jun 12 2017

BRIEF-Exelixis Q1 earnings per share $0.05

* Exelixis announces first quarter 2017 financial results and provides corporate update

May 01 2017

BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan

* Exelixis further reduces indebtedness by repaying silicon valley bank term loan

Mar 29 2017

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 4,912.00 +143.50
Pfizer Inc. (PFE.N) $35.96 -0.01
ArQule, Inc. (ARQL.OQ) $1.14 +0.02
Bayer AG (BAYGn.DE) €110.10 -0.30
Bayer AG (BAYE.F) -- --
Bristol-Myers Squibb Co (BMY.N) $63.36 +0.03
Bristol-Myers Squibb Co (BMYMP.PK) $1,050.00 --
Eli Lilly and Co (LLY.N) $83.91 +0.58
Sanofi SA (SASY.PA) €84.12 +0.25
Amgen, Inc. (AMGN.OQ) $185.76 -0.88

Earnings vs. Estimates